GlassScriptPhysician profile
Julie Anna Bailey
NPI 1457879314
$1,188.93
in general payments reported to CMS, 2019-2025
20 companies · $335 in 2025
The $335 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $36.83 · 2023: $126 · 2024: $690 · 2025: $335.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,152.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,152.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $185.23 | 2024-2025 | |
| Amgen INC. | $135.47 | 2024-2025 | Otezla, Repatha, Evenity |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $108.20 | 2022-2023 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $99.99 | 2024-2025 | Breztri |
| Pfizer INC. | $81.84 | 2024-2025 | |
| Axsome Therapeutics, INC. | $71.80 | 2025 | Auvelity |
| Lilly USA, LLC | $64.14 | 2024 | Mounjaro, Zepbound |
| Sumitomo Pharma America, INC. | $57.31 | 2024-2025 | Gemtesa |
| Phathom Pharmaceuticals, INC. | $57.20 | 2025 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $49.21 | 2024-2025 | Trintellix |
| Teva Pharmaceuticals USA, INC. | $48.67 | 2024 | Austedo Xr |
| Glaxosmithkline, LLC. | $38.57 | 2024 | Bexsero, Shingrix, Arexvy |
| Merck Sharp & Dohme LLC | $34.90 | 2024 | Vaxneuvance, Vaxelis, Gardasil 9 |
| Novartis Pharmaceuticals Corporation | $28.56 | 2022 | |
| Medtronic, INC. | $26.50 | 2023 | Mycarelink |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $24.83 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.88 | 2024 | Jardiance |
| Verona Pharma, INC. | $20.94 | 2025 | Ohtuvayre |
| Novo Nordisk INC | $18.58 | 2024 | |
| Exact Sciences Corporation | $15.11 | 2025 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julie Bailey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.